

## FORM 9

### **NOTICE OF PROPOSED ISSUANCE OF LISTED SECURITIES** **(or securities convertible or exchangeable into listed securities<sup>1</sup>)**

Please complete the following:

Name of Listed Issuer: Global Wellness Strategies Inc. (the "Issuer").

Trading Symbol: LOAN .

Date: September 30, 2021 .

Is this an updating or amending Notice:  Yes  No

If yes provide date(s) of prior Notices: \_\_\_\_\_.

Issued and Outstanding Securities of Issuer Prior to Issuance: 18,544,684 .

Date of News Release Announcing share issuance: September 7, 2021

Closing Market Price on Day Preceding the Issuance of the News Release: \$0.23

#### 1. Private Placement

##### **Table 1A – Summary**

Each jurisdiction in which purchasers reside	Number of Purchasers	Price per Security	Total dollar value (CDN\$) raised in the jurisdiction
Australia	4	0.18	\$568,750.00
Malaysia	1	0.18	\$56,250.00
Total number of purchasers:	5		
Total dollar value of distribution in all jurisdictions:			\$625,000

## Table 1B – Related Persons

Full Name & Municipality of Residence of Placee	Number of Securities Purchased or to be Purchased	Purchase price per Security (CDN\$)	Conversion Price (if Applicable) (CDN\$)	Prospectus Exemption	Total Securities Previously Owned, Controlled or Directed	Payment Date(1)	Describe relations -hip to Issuer (2)
N/A							

<sup>1</sup>An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10.

1. Total amount of funds to be raised:
2. Provide full details of the use of the proceeds. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material. Provide particulars of any proceeds which are to be paid to Related Persons of the Issuer: **N/A**
3. If securities are issued in forgiveness of indebtedness, provide details and attach the debt agreement(s) or other documentation evidencing the debt and the agreement to exchange the debt for securities.
4. Description of securities to be issued:
  - (a) Class:
  - (b) Number:
  - (c) Price per security
  - (d) Voting rights:
5. Provide the following information if Warrants, (options) or other convertible securities are to be issued:
  - (a) Number     **N/A**    .
  - (b) Number of securities eligible to be purchased on exercise of Warrants (or options)     **N/A**    .
  - (c) Exercise price     **N/A**    .
  - (d) Expiry date     **N/A**    .

6. Provide the following information if debt securities are to be issued:
- (a) Aggregate principal amount N/A .
  - (b) Maturity date N/A .
  - (c) Interest rate N/A .
  - (d) Conversion terms N/A .
  - (e) Default provisions N/A .
7. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the placement (including warrants, options, etc.):
- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the placement (name, address. If a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): N/A .
  - (b) Cash N/A .
  - (c) Securities N/A .
  - (d) Other N/A .
  - (e) Expiry date of any options, warrants etc. N/A .
  - (f) Exercise price of any options, warrants etc. N/A .
8. State whether the sales agent, broker, dealer or other person receiving compensation in connection with the placement is Related Person or has any other relationship with the Issuer and provide details of the relationship \_\_\_\_\_  
N/A .
9. Describe any unusual particulars of the transaction (i.e. tax "flow through" shares, etc.).  
N/A .
10. State whether the private placement will result in a change of control.  
N/A .
11. Where there is a change in the control of the Issuer resulting from the issuance of the private placement shares, indicate the names of the new controlling shareholders. N/A

- 
- 
12. Each purchaser has been advised of the applicable securities legislation restricted or seasoning period. All certificates for securities issued which are subject to a hold period bear the appropriate legend restricting their transfer until the expiry of the applicable hold period required by National Instrument 45-102.

**2. Acquisition**

1. Provide details of the assets to be acquired by the Issuer (including the location of the assets, if applicable). The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material: **On August 9, 2021 the company announced that it had entered into a Definitive Agreement with Cannvalate Australia to acquire 100% of their wholly owned subsidiary, Shanti Therapeutics Pty Ltd.**
2. Provide details of the acquisition including the date, parties to and type of agreement (eg: sale, option, license etc.) and relationship to the Issuer. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the acquisition without reference to any other material: **The purchase price of CDN \$2,500,000.00 will be consummated in restricted shares of Global Wellness Strategies Inc. common stock in four (4) installments tendered over an eight (8) month period; representing 100% of the assets of Shanti Therapeutics Pty Ltd.**
- (a) **CDN \$625,000.00 in shares upon completion within 30 days – issued at \$0.18 per share with a four (4) month hold legend;**
- (b) **3 further instalments of \$625,000 every 2 months issued with a base shares price at \$0.20.**
- (c) **An additional contingent consideration of up to CDN \$2,500,000 to Shanti based on the performance of their assets and specific milestones being achieved.**
- (d) **Shanti shall have the right to appoint one director to the board of Global Wellness Strategies Inc.**

3. Provide the following information in relation to the total consideration for the acquisition (including details of all cash, securities or other consideration) and any required work commitments:
- (a) Total aggregate consideration in Canadian dollars: **\$2,500,000 as per schedule noted above.**
  - (b) Cash: **N/A** .
  - (c) Securities (including options, warrants etc.) and dollar value: \_\_\_\_\_ .
  - (d) Other: **N/A** .
  - (e) Expiry date of options, warrants, etc. if any: **N/A** .
  - (f) Exercise price of options, warrants, etc. if any: **N/A** .
  - (g) Work commitments: **N/A** .
4. State how the purchase or sale price was determined (e.g. arm's-length negotiation, independent committee of the Board, third party valuation etc).  
**Arm's-length negotiation.**
5. Provide details of any appraisal or valuation of the subject of the acquisition known to management of the Issuer: **N/A** .
6. The names of parties receiving securities of the Issuer pursuant to the acquisition and the number of securities to be issued are described as follows:

Name of Party (If not an individual, name all insiders of the Party)	Number and Type of Securities to be Issued	Dollar value per Security (CDN\$)	Conversion price (if applicable)	Prospectus Exemption	No. of Securities, directly or indirectly, Owned, Controlled or Directed by Party	Describe relationship to Issuer <sup>(1)</sup>
Darryl Davies	1,041,666 common shares	Deemed at 0.18 for share	n/a	NI45-106 2.12 [Asset acquisition]	Nil	N/a
Sudhanshu Agarwal	1,041,666 common shares	Deemed at 0.18 for share	n/a	NI45-106 2.12 [Asset acquisition]	Nil	N/a
Con Stough	34,724 common shares	Deemed at 0.18 for share	n/a	NI45-106 2.12 [Asset acquisition]	Nil	N/a
Parim Singh	312,500 common shares	Deemed at 0.18 for share	n/a	NI45-106 2.12 [Asset acquisition]	Nil	N/a
Umeera Maan	1,041,666 common shares	Deemed at 0.18 for share	n/a	NI45-106 2.12 [Asset acquisition]	Nil	N/a

7. Details of the steps taken by the Issuer to ensure that the vendor has good title to the assets being acquired: **Due Diligence by the Corporations legal counsel, management and the Board of directors.**
8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the acquisition (including warrants, options, etc.):
- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the acquisition (name, address. If a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): N/A

- (b) Cash N/A .
- (c) Securities N/A .
- (d) Other N/A .
- (e) Expiry date of any options, warrants etc. N/A .
- (f) Exercise price of any options, warrants etc. N/A .

9. State whether the sales agent, broker or other person receiving compensation in connection with the acquisition is a Related Person or has any other relationship with the Issuer and provide details of the relationship. N/A

\_\_\_\_\_

\_\_\_\_\_

10. If applicable, indicate whether the acquisition is the acquisition of an interest in property contiguous to or otherwise related to any other asset acquired in the last 12 months. N/A

\_\_\_\_\_

\_\_\_\_\_

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance on behalf of the Issuer.
2. As of the date hereof there is not material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 9 Notice of Issuance of Securities is true.

Dated September 30, 2021.

Meris Kott  
Name of Director or Senior Officer

/s/ "Meris Kott  
Signature

President & CEO  
Official Capacity